Scholars Central

Conference abstractPublished 7 May 2018

Preliminary studies regarding biocompatibility of encapsulated dopamine in a nanoporous matrix of TiO2 as a material for store and release of dopamine

Authors: P Vergara-Aragon, G Valverde-Aguilar, M Vazquez-Garcia, B Hernandez-Tellez, A L Camacho Alvarez, M J Jimenez Gutierrez, L C Ibarra Montenegro, H Gonzalez Sanchez, D Santiago Lopez

National Autonomous University of Mexico, Mexico Instituto Politecnico Nacional, Mexico Universidad Autonoma de la Ciudad de Mexico, Mexico

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The development of formulations based on titanium dioxide to store dopamine (TiO2/DA) minimizes the oxidation of it by protecting it from direct exposure to natural light and air. It also fulfills a second function that is the release of dopamine (DA) for long periods in a rat model of hemiparkinsonism. A critical point is the toxicity of these materials that has led us to perform biocompatibility tests on these TiO2/DA implants. The first biocompatibility studies on TiO2/DA implant are presented here. Presterilized samples of the matrix were implanted subcutaneously and intraperitoneally in male Wistar rats. Scanning electron microscopy and histological examination of implanted samples and surrounding tissues were performed; subcutaneous implant was 0.095 g/DA per 20 ml of TiO2. Histological examination of implanted samples and surrounding tissues revealed no evidence of acute or chronic foreign body inflammatory response. The fibrous capsules surrounding the implant remained thin (<100 Ã?Â?Ã?¼m) after more than three months in situ, while the surrounding tissue remained well vascularized; intraperitoneal implant was 0.02 ml/DA per 20 ml of TiO2. The histological analysis for the liver, heart, lung, kidney, spleen, muscles and brain did not show structural macroscopic changes. It did not show an inflammatory response either (TNF-a, IL-6 and cellular infiltration), between the control group and the experimental groups. Also, the implants lingered encapsulated on tissue after three months; intraperitoneal implant was 0.13 g/DA per 20 ml of TiO2. It was observed that a mild inflammatory effect and the presence of mononucleocytes within the group which received the highest dose of TiO2/DA. The results of this analysis suggest that there is no contamination across the organs due to the implants. It is possible to suggest the compatibility of the TiO2/DA implant with the rat tissue, and thus, justify a further investigation about its potential use as biomaterial for storing and releasing drugs. Recent Publications 1. P Vergara-AragÃ?Â?Ã?³n (2017) Is it possible to reverse the motor alterations with dopamine supply content in an amorphuous matrix in a hemiparkinsonian rat model? Phamaceutical Reg Affairs 6(1):53. 2. S HernÃ?Â?Ã?¡ndez Castro and P Vergara AragÃ?Â?Ã?³n (2017) A PET study with [11-C] raclopride in hermiparkinsonism model: preliminary results on the effect of a TiO2 DA matrix implanted in the caudate nucleus. Phamaceutical Reg Affairs 6(1):52. 3. Blanca Meza Aupart and Vergara AragÃ?Â?Ã?³n P (2017) Evaluation of the effects that produce a micro-implant with dopamine stabilized and inserted in the caudate nucleus in hemiparkinsonism rat model induced on motor activity and its relationship to the levels of dopamine. Phamaceutical Reg Affairs 6(1):54. 4. VelÃ?Â?Ã?¡zquez-Paniagua M, Ana MarÃ?Â?Ã?­a VÃ?Â?Ã?¡zquez-Ã?Â?Ã?lvarez, MarÃ?Â?Ã?­a Guadalupe Valverde-Aguilar y and Patricia Vergara-AragÃ?Â?Ã?³n (2016) Current treatments in ParkinsonÃ?¢Ã?Â?Ã?Â?s including the proposal of an innovative dopamine micro implant. Revista del Hospital General de MÃ?Â?Ã?©xico. Rev Med Hosp Gen Mex. 79(2):79Ã?¢Ã?Â?Ã?Â?87. 5. Valverde-Aguilar G, Prado-Prone G, Vergara-AragÃ?Â?Ã?³n P, GarcÃ?Â?Ã?­a-Macedo J, Santiago P, et al. (2014) Photoconductivity studies on nanoporous TiO2/dopamine films prepared by solÃ?¢Ã?Â?Ã?Â?gel method. Applied Physics A 116(3):1075Ã?¢Ã?Â?Ã?Â?1084.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Pharmaceutical Regulatory Affairs: Open Access.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalPharmaceutical Regulatory Affairs: Open Access
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “P Vergara-Aragon”
  • BylineArticles whose byline prints “G Valverde-Aguilar”
  • BylineArticles whose byline prints “M Vazquez-Garcia”
  • BylineArticles whose byline prints “B Hernandez-Tellez”
  • BylineArticles whose byline prints “A L Camacho Alvarez”
  • BylineArticles whose byline prints “M J Jimenez Gutierrez”
  • BylineArticles whose byline prints “L C Ibarra Montenegro”
  • BylineArticles whose byline prints “H Gonzalez Sanchez”